Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies
Wenwen Yang, Caining Lei, Shaoming Song, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 24

Showing 24 citing articles:

Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity
Zhangchi Dongye, Jian Li, Yuzhang Wu
British Journal of Cancer (2022) Vol. 127, Iss. 9, pp. 1584-1594
Open Access | Times Cited: 63
Metal-organic frameworks (MOFs) as biomolecules drug delivery systems for anticancer purposes
Michele Coluccia, Valeria Parisse, Paolo Guglielmi, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114801-114801
Closed Access | Times Cited: 63
Lymphangiogenesis orchestrating tumor microenvironment: Face changing in immunotherapy
J Zhang, Hao Li, Mengjie Zhang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189278-189278
Closed Access | Times Cited: 1
The Tumor Stroma of Squamous Cell Carcinoma: A Complex Environment That Fuels Cancer Progression
Alexandra Buruiană, Bogdan‐Alexandru Gheban, Ioana‐Andreea Gheban‐Roșca, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1727-1727
Open Access | Times Cited: 7
Hypoxia inducible factor-1ɑ as a potential therapeutic target for osteosarcoma metastasis
Jianghu Zhou, Fengjun Lan, Miao Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Single-Cell Profiling Reveals Heterogeneity of Primary and Lymph Node Metastatic Tumors and Immune Cell Populations and Discovers Important Prognostic Significance of CCDC43 in Oral Squamous Cell Carcinoma
Zhenyu Wang, Hongbo Zhang, Yanan Zhai, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
Liposome-based nanomedicine for immune checkpoint blocking therapy and combinatory cancer therapy
Haoyuan Zhou, Cui‐Yun Yu, Hua Wei
International Journal of Pharmaceutics (2024) Vol. 652, pp. 123818-123818
Closed Access | Times Cited: 4
Unveiling TNFAIP8L2-related Immune Evasion Mechanisms in Colorectal Cancer
David H. Mauki, Ping Li, Shuyao Lang, et al.
Deleted Journal (2025), pp. 100041-100041
Open Access
Biomimetic nanocarriers harnessing microbial metabolites usher the path for brain disease therapy
Ying Gong, Zhijun Liu, Piaopiao Zhou, et al.
Nano TransMed (2023) Vol. 2, Iss. 4, pp. 100020-100020
Open Access | Times Cited: 10
Prognostic Impact of the Maximal Evaluable Lesion Size in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Combination Therapy
Yoshie Mita, Jun Teishima, Takuto Hara, et al.
International Journal of Urology (2025)
Closed Access
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
Mei‐Yin Zhang, Chao-jun Liu, Jing Tu, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Discovery of novel resorcinol biphenyl ether-based macrocyclic small molecules as PD-1/PD-L1 inhibitors with favorable pharmacokinetics for cancer immunotherapy
Zichao Yang, Ziqing Liu, Chenglong Xu, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106740-106740
Closed Access | Times Cited: 6
Immune subtype identification and multi-layer perceptron classifier construction for breast cancer
Xinbo Yang, Yuanjie Zheng, Xianrong Xing, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 9
The predictive value of plasma exosomal lncRNAs/mRNAs in NSCLC patients receiving immunotherapy
Yue Wang, Shuhui Cao, Jingwen Li, et al.
Advances in Medical Sciences (2023) Vol. 68, Iss. 1, pp. 86-93
Closed Access | Times Cited: 5
A Novel Four-Gene Prognostic Signature for Prediction of Survival in Patients with Soft Tissue Sarcoma
Changwu Wu, Siming Gong, Georg Osterhoff, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5837-5837
Open Access | Times Cited: 9
MUTYH is a potential prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma
Fan Yang, Qinghai Lian, Beibei Ni, et al.
Liver Research (2022) Vol. 6, Iss. 4, pp. 258-268
Open Access | Times Cited: 5
Development and validation of novel prognostic models for zinc finger proteins-related genes in soft tissue sarcoma
Junqing Li, Quan Zhou, Changsheng Zhang, et al.
Aging (2023)
Open Access | Times Cited: 2
ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas
Yue Ming, Chunyuan Luo, Beihong Ji, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Fatal myositis and myasthenia induced by atezolizumab for the treatment of hepatocellular carcinoma
Jérôme Dumortier, Marie Simon, Françoise Bouhour
Clinics and Research in Hepatology and Gastroenterology (2021) Vol. 46, Iss. 3, pp. 101854-101854
Closed Access | Times Cited: 4
IRF4: A potential prognostic biomarker for immunotherapy in NSCLC
Qian Zhao, Butuo Li, Yiyue Xu, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113411-113411
Closed Access
Heterogeneous immune landscapes and macrophage dynamics in primary and lung metastatic adenoid cystic carcinoma of the head and neck
Xuelian Wang, Tingyao Ma, Hongfei Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Molecular biomarkers for facilitating genome‑directed precision medicine in gynecological cancer (Review)
Takeo Minaguchi, Ayumi Shikama, Azusa Akiyama, et al.
Oncology Letters (2023) Vol. 26, Iss. 4
Open Access
[Advances in Predictive Research of Immune Checkpoint Inhibitors-related 
Adverse Events].
Jing Zhang, Xueqin Chen, Shenglin Ma
PubMed (2023) Vol. 26, Iss. 10, pp. 789-794
Closed Access
Research Progress in Immunotherapy of Esophageal Squamous Carcinoma
彩耘 李
Advances in Clinical Medicine (2022) Vol. 12, Iss. 01, pp. 545-548
Closed Access
Study of PD-1 Customization and Autoimmune T Cells for Advanced Colorectal Cancer with High MSI Expression
Na Li, Xiaojie Zhang, Yinsong Zhang, et al.
Contrast Media & Molecular Imaging (2022) Vol. 2022, Iss. 1
Open Access
Page 1

Scroll to top